{"entity":{"id":"linnaeus-therapeutics","kind":"company","name":"Linnaeus Therapeutics","aka":["Linnaeus Therapeutics, Inc."],"tldr":"Linnaeus Therapeutics is a New Jersey biotech whose oral drug LNS8801 activates the oestrogen receptor GPER, a pathway that pushes melanoma cells to stop dividing and become visible to the immune system.","summary":"Linnaeus Therapeutics develops LNS8801, an orally available agonist of the G protein-coupled oestrogen receptor (GPER), based on University of Pennsylvania research showing that GPER activation drives melanoma differentiation and lowers c-Myc. LNS8801 has been tested alone and with pembrolizumab in phase 1/2 trials in cutaneous melanoma and uveal melanoma, including patients who had progressed on checkpoint inhibitors.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["lns8801"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Haddonfield, New Jersey","country":"US","companyType":"biotech","investors":[],"funding":[]},"route":"/companies/linnaeus-therapeutics/","neighbours":{"drug":[{"id":"lns8801","kind":"drug","name":"LNS8801","route":"/drugs/lns8801/"}]}}